Tatiana Victoni

Dr. Tatiana Victoni

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
TVTatiana Victoni
Tatiana Victoni
EBEmiliano Barreto
Emiliano Barreto
VLVincent Lagente
Vincent Lagente
VCVinicius Frias Carvalho
Vinicius Frias Carvalho
Inflammatory lung disease results in a high global burden of death and disability. There are no effective treatments for the most severe forms of many inflammatory lung diseases, such as chronic obstructive pulmonary disease, emphysema, corticosteroid‐resistant asthma, and coronavirus disease 2019; hence, new treatment options are required. Here, we review the role of oxidative imbalance in the development of difficult‐to‐treat inflammatory lung diseases. The inflammation‐induced overproduction of reactive oxygen species (ROS) means that endogenous antioxidants may not be sufficient to prevent oxidative damage, resulting in an oxidative imbalance in the lung. In turn, intracellular signaling events trigger the production of proinflammatory mediators that perpetuate and aggravate the inflammatory response and may lead to tissue damage. The production of high levels of ROS in inflammatory lung diseases can induce the phosphorylation of mitogen‐activated protein kinases, the inactivation of phosphoinositide 3‐kinase (PI3K) signaling and histone deacetylase 2, a decrease in glucocorticoid binding to its receptor, and thus resistance to glucocorticoid treatment. Hence, antioxidant treatment might be a therapeutic option for inflammatory lung diseases. Preclinical studies have shown that antioxidants (alone or combined with anti‐inflammatory drugs) are effective in the treatment of inflammatory lung diseases, although the clinical evidence of efficacy is weaker. Despite the high level of evidence for the efficacy of antioxidants in the treatment of inflammatory lung diseases, the discovery and clinical investigation of safer, more efficacious compounds are now a priority.

21 June 2017 in Respiratory Research
Verified
Journal Article
Open access
PDF file
TVTatiana Victoni
Tatiana Victoni
HSHélène Salvator
Hélène Salvator
CACharlotte Abrial
Charlotte Abrial
MBMarion Brollo
Marion Brollo
LPLuis Cristóvão Porto
Luis Cristóvão Porto
PDPhilippe Devillier
Philippe Devillier
β2-adrenoceptor agonists have been shown to reduce the lipopolysaccharide (LPS)-induced cytokine release by human monocyte-derived macrophages (MDMs). We compare the expression of β2-adrenoceptors and the inhibitory effect of formoterol and salmeterol on the LPS-induced release of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and a range of chemokines (CCL2, 3, 4, and IL-8) by human lung macrophages (LMs) and MDMs. LMs were isolated from patients undergoing resection and MDMs were obtained from blood monocytes in the presence of GM-CSF. LMs and MDMs were incubated in the absence or presence of formoterol or salmeterol prior to stimulation with LPS. The effects of formoterol were also assessed in the presence of the phosphodiesterase inhibitor roflumilast. LPS-induced cytokine production was higher in LMs than in MDMs. Salmeterol and formoterol exerted an inhibitory effect on the LPS-induced production of TNF-α, IL-6, CCL2, CCL3, and CCL4 in MDMs. In contrast, the β2-adrenoceptor agonists were devoid of any effect on LMs - even in the presence of roflumilast. The expression of β2-adrenergic receptors was detected on Western blots in MDMs but not in LMs. Concentrations of β2-adrenoceptor agonists that cause relaxation of the human bronchus can inhibit cytokine production by LPS-stimulated MDMs but not by LMs.

Verified
Journal Article
Open access
PDF file
CSCamila Oliveira da Silva
Camila Oliveira da Silva
ACAndréa Monte Alto Costa
Andréa Monte Alto Costa
MRMariana Renovato
Mariana Renovato
FNFilipe Jorge Viana Nascimento
Filipe Jorge Viana Nascimento
Samuel ValencaSamuel Valenca
Samuel Valenca
TVTatiana Victoni
Tatiana Victoni
Alveolar macrophages play a central role in the pathogenesis of chronic obstructive pulmonary disease (COPD). Monocytes are recruited from blood during inflammation and then mature into alveolar macrophages. The aim of this study was to investigate the effect of cigarette smoke (CS) at different times in lung macrophages and monocytes from blood and bone marrow in mice. Male mice (C57BL/6, n = 45) were divided into groups: control, CS 5 days, CS 14 days and CS 30 days. Five days’ CS exposure induced a pronounced influx of neutrophils and macrophages in the lung associated with increased levels of keratinocyte chemoattractant (KC), tumor necrosis factor-α (TNF-α), nitric oxide (NO) and matrix metalloproteinase (MMP)-12. After 14 days of CS exposure, neutrophil recruitment and cytokine production were greatly reduced. Moreover, chronic CS exposure led to increased recruitment of macrophages (with high expression of CD206), transforming growth factor-β (TGF-β) production as well as no detection of TNF-α, interleukin (IL)-6 and KC. CS can also change the monocyte phenotype in the blood and bone marrow, with an increase in Ly6Clow cells. These results show for the first time that CS can change not only macrophage polarization but also monocyte. These results suggest that continued recruitment of Ly6Clow monocytes may help the distinct renewing macrophage M2 population required for COPD progression.

1 April 2018 in Pulmonary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
ENEmmanuel Naline
Emmanuel Naline
SDStanislas Grassin Delyle
Stanislas Grassin Delyle
HSHélène Salvator
Hélène Salvator
MBMarion Brollo
Marion Brollo
CFChristophe Faisy
Christophe Faisy
PDPhilippe Devillier
Philippe Devillier

1 January 2016 in International Immunopharmacology
Verified
Journal Article
Closed access
TVTatiana Victoni
Tatiana Victoni
TGThomas Gicquel
Thomas Gicquel
ABAude Bodin
Aude Bodin
MDMarion Daude
Marion Daude
HTHermann Tenor
Hermann Tenor
EBElisabeth Boichot
Elisabeth Boichot

1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
VCVinicius Frias Carvalho
Vinicius Frias Carvalho
EBEmiliano Barreto
Emiliano Barreto
TVTatiana Victoni
Tatiana Victoni
VLVincent Lagente
Vincent Lagente
In the uncontrolled inflammatory response, reactive oxygen species (ROS) overwhelm the cellular antioxidant defense system, resulting in direct or indirect ROS-mediated damage on nucleic acids, proteins, and lipids. In the acute inflammatory process, high intracellular levels of ROS have been implicated in an impairment of resolution of inflammation and cellular injury, resulting in chronic inflammation. The imbalance due to excess oxidants reduces the ability of the cell to mount an effective antioxidant response and is implicated in inflammatory diseases from the airway and lung. In this special issue, we gathered diverse studies expanding our knowledge about the effects of ROS imbalance and/or signaling on the development or aggravation of pulmonary diseases as well as the effects of compounds with antioxidant properties on acute or chronic lung diseases.